TW202112818A - 產生抗α4β7抗體之方法 - Google Patents

產生抗α4β7抗體之方法 Download PDF

Info

Publication number
TW202112818A
TW202112818A TW109119563A TW109119563A TW202112818A TW 202112818 A TW202112818 A TW 202112818A TW 109119563 A TW109119563 A TW 109119563A TW 109119563 A TW109119563 A TW 109119563A TW 202112818 A TW202112818 A TW 202112818A
Authority
TW
Taiwan
Prior art keywords
vedolizumab
composition
less
buffer
hours
Prior art date
Application number
TW109119563A
Other languages
English (en)
Chinese (zh)
Inventor
黛布拉 亞美利
蘇西 Ｒ 卡特
麥可 Ｅ 多蘭
妮可 希洛
阿米塔瓦 昆都
艾咪 米勒
喬治 帕克斯
Original Assignee
美商千禧製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商千禧製藥公司 filed Critical 美商千禧製藥公司
Publication of TW202112818A publication Critical patent/TW202112818A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW109119563A 2019-06-10 2020-06-10 產生抗α4β7抗體之方法 TW202112818A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962859494P 2019-06-10 2019-06-10
US62/859,494 2019-06-10

Publications (1)

Publication Number Publication Date
TW202112818A true TW202112818A (zh) 2021-04-01

Family

ID=73781728

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109119563A TW202112818A (zh) 2019-06-10 2020-06-10 產生抗α4β7抗體之方法

Country Status (14)

Country Link
US (1) US20220267449A1 (https=)
EP (1) EP3980466A4 (https=)
JP (2) JP7624414B2 (https=)
CN (3) CN114375307B (https=)
AR (1) AR119270A1 (https=)
AU (1) AU2020290943A1 (https=)
BR (1) BR112021024897A2 (https=)
CA (1) CA3143167A1 (https=)
IL (1) IL288825A (https=)
MA (1) MA56129A (https=)
MX (1) MX2021015300A (https=)
PL (1) PL439809A1 (https=)
TW (1) TW202112818A (https=)
WO (1) WO2020252069A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12433947B2 (en) 2018-04-10 2025-10-07 Dr. Reddy's Laboratories Limited Stable formulations of therapeutic antibody
WO2019198099A1 (en) * 2018-04-10 2019-10-17 Dr. Reddy's Laboratories Limited Stable antibody formulation
WO2023007516A1 (en) * 2021-07-29 2023-02-02 Dr. Reddy’S Laboratories Limited Method to control high molecular weight aggregates in an antibody composition
EP4380948A4 (en) * 2021-08-05 2025-07-16 Dr Reddys Laboratories Ltd METHOD FOR PURIFYING AN ANTIBODY COMPOSITION BY MEANS OF CATION EXCHANGE CHROMATOGRAPHY
WO2023031965A1 (en) * 2021-09-03 2023-03-09 Dr. Reddy’S Laboratories Limited Method to obtain a purified antibody composition
WO2024233992A2 (en) * 2023-05-11 2024-11-14 Trophogen, Inc. Methods of manufacturing highly glycosylated glycoprotein hormones and their analogs
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2014142882A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
PL3116891T3 (pl) * 2014-03-10 2020-07-27 Richter Gedeon Nyrt. Oczyszczanie immunoglobuliny z zastosowaniem etapów wstępnego oczyszczania
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive

Also Published As

Publication number Publication date
CN114375307B (zh) 2025-12-05
BR112021024897A2 (pt) 2022-01-18
PL439809A1 (pl) 2022-12-05
CN121736106A (zh) 2026-03-27
EP3980466A4 (en) 2023-06-07
WO2020252069A1 (en) 2020-12-17
JP7624414B2 (ja) 2025-01-30
CA3143167A1 (en) 2020-12-17
CN119859188A (zh) 2025-04-22
US20220267449A1 (en) 2022-08-25
EP3980466A1 (en) 2022-04-13
JP2025063035A (ja) 2025-04-15
MX2021015300A (es) 2022-02-03
AU2020290943A1 (en) 2022-02-03
JP2022536486A (ja) 2022-08-17
CN114375307A (zh) 2022-04-19
AR119270A1 (es) 2021-12-09
MA56129A (fr) 2022-04-13
IL288825A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
JP7624414B2 (ja) 抗α４β７抗体の産生方法
US20110144311A1 (en) Methods for purifying antibodies using protein a affinity chromatography
CN107446044B (zh) 一种纯化抗体的方法及所用缓冲液
JP7753105B2 (ja) 抗体の精製方法及びその組成物
CN105121469A (zh) 用于增加蛋白质的焦谷氨酸形成的方法
JP2022536486A5 (https=)
US12139510B2 (en) Process of purification of protein
TW202128131A (zh) 重組抗程式性細胞死亡受體1和抗分化抗原簇137雙特異性抗體製劑及其用途
WO2021220252A1 (en) An improved process of purification of protein
RU2852606C2 (ru) СПОСОБЫ ПОЛУЧЕНИЯ АНТИТЕЛА ПРОТИВ α4β7
WO2011085574A1 (zh) 全人TNFα单克隆抗体及其制备方法与应用
US20260001935A1 (en) Methods of characterizing and purifying vegf receptor fusion protein
US20250129117A1 (en) Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250296015A1 (en) An improved process of purification of protein
BR122024018491A2 (pt) Métodos de purificação de anticorpos e composições dos mesmos